HELP Publishes Nature Medicine Phase 2a SPL026 MDD Trial Results Showing -7.35 MADRS Reduction, 35% Response, 29% Remission, Phase 2 GAD Data Expected Q1 2026
Cybin Inc. Common Stock · Now $4.69
Post-detection moves
1h
—
1d
—
3d
—
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS